Exagen (NASDAQ:XGN) Upgraded at B. Riley

B. Riley upgraded shares of Exagen (NASDAQ:XGN) to a strong-buy rating in a research report sent to investors on Wednesday,Zacks.com reports.

Other research analysts have also issued research reports about the company. KeyCorp raised Exagen from a “sector weight” rating to an “overweight” rating and set a $12.00 price target for the company in a research report on Wednesday, July 30th. Canaccord Genuity Group upped their price target on Exagen from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Wednesday, July 30th. UBS Group reaffirmed an “overweight” rating on shares of Exagen in a research report on Thursday, May 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price target on shares of Exagen in a research report on Wednesday, July 30th. Finally, Craig Hallum started coverage on Exagen in a research report on Wednesday, July 23rd. They issued a “buy” rating and a $12.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $12.00.

Exagen Trading Down 2.6%

NASDAQ XGN opened at $9.74 on Wednesday. The stock has a 50-day moving average of $8.70 and a 200-day moving average of $6.56. The firm has a market cap of $214.28 million, a PE ratio of -10.94 and a beta of 1.60. The company has a current ratio of 4.95, a quick ratio of 4.95 and a debt-to-equity ratio of 1.06. Exagen has a 1-year low of $2.38 and a 1-year high of $10.34.

Exagen (NASDAQ:XGN) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $16.25 million. Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%. Exagen has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Exagen will post -0.88 EPS for the current year.

Institutional Trading of Exagen

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Northern Trust Corp grew its stake in shares of Exagen by 16.7% in the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock worth $75,000 after buying an additional 2,630 shares during the last quarter. Toronto Dominion Bank purchased a new stake in shares of Exagen in the 4th quarter worth approximately $3,655,000. Palumbo Wealth Management LLC grew its stake in shares of Exagen by 14.4% in the 1st quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company’s stock worth $356,000 after buying an additional 12,501 shares during the last quarter. Huntleigh Advisors Inc. grew its stake in shares of Exagen by 16.8% in the 1st quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company’s stock worth $298,000 after buying an additional 11,939 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Exagen in the 2nd quarter worth approximately $133,000. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).